Who We Are?
OrthoSera is a regenerative medicine company harnessing the power of blood serum for human diseases. Our R&D is currently focused on bone grafting, osteoarthritis, wound healing, as well as dental and orthopedic indications. Blood serum has a high regenerative potential and based on this fact OrthoSera has already developed two technologies.
BoneAlbumin is essentially a serum albumin enhanced bone allograft that was shown to activate bone marrow stem cells leading to faster and better bone healing. This tissue product is already in commercial stage with two double-blind clinical studies proving its effectiveness in sports surgery and dentistry. Our next technology takes this concept even further, as we use a proprietary method to isolate a specific, growth-factor rich serum fraction (hyperacute serum or hypACT™) that has shown superior effects in promoting cell proliferation in osteoarthritic bone, cartilage, and mesenchymal stem cells among others.
Hyperacute serum is also patent-covered and can be applied at the bedside with our CE-marked medical device, hypACT inject.
Learn About Our Leading Technologies
Hyperacute serum therapy: pilot first-in-man results in knee osteoarthritisRead more
Two peer-reviewed studies showed that hypACT outperforms PRP as a regenerative serum. Krems an der Donau, Austria, 15 January 2018 – Hyperacute serum, a variety of...Read more